Risks of Recovering and Monetizing R&D Investments
First written in FY2016. 22 of 23 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2026: 17 of 35 companies on the "Worse" side.
81 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥453 million. There were no material changes in the status of the Group's R&D activities during the current interim consolidated accounting period.」
The company states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥542 million. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」
The company states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2023-Q3RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
Regarding its previous assessment of the risks related to recovering and monetizing R&D investments, the company continues to state that there have been no material changes in its R&D activities. - FY2023-Q2RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
Regarding the traditional risk assessment concerning the recovery and monetisation of R&D investment, the company states that there have been no material changes to its R&D activities. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current cumulative consolidated period were ¥258 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current cumulative consolidated period.」
The company states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2022RestatedAnnual report
「The Group may be unable to generate sufficient revenue due to lost opportunities for commercialization or sudden changes in the market environment, which could affect its operating results, financial condition and other aspects of its business.」
The company continues to disclose the risk that R&D investments may fail to generate revenue due to lost opportunities for commercialization or changes in the market. - FY2022-Q3RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
Regarding its previous assessment of the risks related to recovering and monetizing R&D investments, the company continues to state that there have been no material changes in its R&D activities. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥300 million. There were no material changes in the status of the Group's R&D activities during the second quarter of the current consolidated cumulative period.」
The company states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2021-Q3RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
The company states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2021-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥107 million. There were no significant changes in the status of the Group’s research and development activities during the first quarter of the current consolidated cumulative period.」
Although the company continues to record R&D expenses, it states that there have been no material changes in the status of its R&D activities and continues its previous assessment of the risks related to recovering and monetizing investments. - FY2020-Q3RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the cumulative third quarter of the current consolidated fiscal year.」
The company states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2020-Q2RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the cumulative second quarter of the current consolidated fiscal year.」
The company states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2020-Q1RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the cumulative first quarter of the current consolidated fiscal year.」
The company states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2019RestatedAnnual report
「The Group may be unable to generate sufficient revenue due to lost opportunities for commercialization or sudden changes in the market environment, which could affect its operating results, financial condition and other aspects of its business.」
The company continues to disclose the risk that R&D investments may fail to generate sufficient revenue due to lost opportunities for commercialization or changes in the market. - FY2019-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥408 million. There were no significant changes in the status of the Group’s research and development activities during the third quarter of the current consolidated cumulative period.」
The company states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the second quarter of the current consolidated cumulative period were ¥281 million. There were no material changes in the status of the Group's R&D activities during the second quarter of the current consolidated cumulative period.」
Although the company continues its R&D activities, it states that there have been no material changes in their status and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2019-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥94 million. There were no significant changes in the status of the Group’s research and development activities during the first quarter of the current consolidated cumulative period.」
The company states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing R&D investments. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥273 million. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」
Although the company recorded R&D expenses of ¥273 million, it states that there have been no material changes in its R&D activities and continues its previous assessment of the risks related to recovering and monetizing investments. - FY2018-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥155 million. There were no significant changes in the status of the Group’s research and development activities during the second quarter of the current consolidated cumulative period.」
Although the company continues to record R&D expenses, it states that there have been no material changes in the status of its R&D activities, and no new events related to the risks of recovering and monetizing investments have been disclosed. - FY2017RestatedAnnual report
「Information on the Group's R&D activities is provided in Section 2, Business Overview, 6. Research and Development Activities. However, the Group may be unable to generate sufficient revenue due to lost opportunities for commercialization or sudden changes in the market environment, which could affect its operating results, financial condition and other aspects of its business.」
While limiting R&D expenses to ¥906 million, the company continues to recognize the risk of failing to achieve revenue due to lost opportunities for commercialization or changes in the market. - FY2017-Q3RestatedAnnual report
「Total R&D expenses for the third quarter of the current consolidated cumulative period were ¥776 million. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」
The company recorded R&D expenses of ¥776 million and stated that there have been no material changes in the status of its R&D activities. - FY2017-Q1RestatedAnnual report
「Total R&D expenses for the first quarter of the current consolidated cumulative period were ¥189 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company recorded R&D expenses of ¥189 million and stated that there have been no material changes in the status of its R&D activities. - FY2016MaterialisedAnnual report
「During the current consolidated fiscal year, the company incurred substantial R&D expenses of ¥3,931 million, including costs related to discontinuing some R&D projects.」
The company disclosed the risk of failing to achieve revenue due to lost opportunities for commercialization or changes in the market environment, and incurred substantial R&D expenses and costs related to discontinuing some development projects during the current fiscal year.